Abbott Reports Third-Quarter 2026 Results and Reaffirms Full-Year EPS Guidance
– Third-quarter reported sales growth of 14.5 percent; comparable sales growth of 7.0 percent
– Expands portfolio with key new product approvals ABBOTT PARK, Ill., Oct. 21, 2026 — Abbott today announced financial results for the third quarter ended Sept. 30, 2026.
• Third-quarter sales increased 14.5 percent on a reported basis and 7.0 percent on a comparable basis.
• Third-quarter GAAP diluted EPS of $0.53 and adjusted diluted EPS of $1.42, which excludes specified items.
• Abbott projects full-year 2026 comparable sales growth to be approximately 6.0 percent 1 .
• Abbott reaffirms the midpoint of previously provided full-year 2026 adjusted diluted EPS guidance range and tightens the range to $5.50 to $5.55.
• In August, Abbott announced U.S. Food and Drug Administration (FDA) approval for Libre® Duo, the world's first dual glucose-ketone biowearable sensor. By providing real-time visibility into glucose and ketone levels, this new technology helps optimize the management of diabetes by detecting rising ketone levels, which can lead to diabetic ketoacidosis, a serious health condition for people with diabetes.
• In August, Abbott announced that the company received CE Mark for its Amulet 360™ Left Atrial Appendage (LAA) Occluder, a next-generation device designed to reduce the risk of stroke in patients with atrial fibrillation (AFib).
• In August, Abbott announced the launch of Similac® 360 Total Care® Made With Whole Milk — the first and only commercially sterile, ready-to-feed liquid infant formula made with whole milk in the United States.
• In September, Abbott announced FDA approval for its TactiFlex™ Duo Ablation Catheter, Sensor Enabled™, designed to deliver both pulsed field ablation (PFA) and radiofrequency (RF) energy to treat patients battling atrial fibrillation.
• In September, Abbott launched SimpleScreen™ CRC, an FDA-approved, blood-based colorectal cancer screening test for adults age 45 and older who are at average risk for the disease.
"Abbott delivered strong third-quarter results, reflecting balanced growth across our portfolio," said Robert B. Ford, chairman and chief executive officer, Abbott. "With strong performance across multiple businesses and a robust pipeline of innovation, we are well-positioned to deliver sustainable growth in the years ahead." Page 1 of 21
Management believes that measuring sales growth on a comparable basis is an appropriate way for investors to best understand the underlying performance of the business. Comparable sales growth includes the prior and current year sales of Exact Sciences, a cancer diagnostics company that Abbott acquired on March 23, 2026. Comparable sales growth excludes the impact of foreign exchange and revenue in both the prior and current year related to compensation payments that Abbott's Structural Heart business received as part of a multi-year agreement with a competitor. The final payment under this agreement was recognized in the first quarter of 2026.
Note: In order to compute results excluding the impact of exchange rates, current year U.S. dollar sales are multiplied or divided, as appropriate, by the current year average foreign exchange rates and then those amounts are multiplied or divided, as appropriate, by the prior year average foreign exchange rates.
Sales 3Q26 ($ in Total Pediatric Adult millions) U.S. 958 577 381 International 1,304 486 818 Total reported 2,262 1,063 1,199
Worldwide Nutrition sales increased 5.1 percent on a reported basis and 4.9 percent on a comparable basis in the third quarter.
Worldwide Nutrition results were driven by broad-based growth across the portfolio, including sales growth of nearly 9.0 percent in Worldwide Pediatric.
On a sequential basis, Worldwide Nutrition sales increased $118 million compared to the second quarter of 2026.
Worldwide Diagnostics sales increased 46.7 percent on a reported basis and 6.4 percent on a comparable basis in the third quarter.
Worldwide Core Laboratory Diagnostics results were driven by balanced growth across major geographic regions including the U.S., Europe, Japan, and Latin America.
Cancer Diagnostics results were driven by growth of Cologuard® and also reflect contributions to growth from the precision oncology and international businesses.
*Beginning in 2026, Abbott aggregated its previously reported Rapid Diagnostics, Molecular Diagnostics, and Point of Care businesses into the Rapid and Molecular Diagnostics business. On March 23, 2026, Abbott completed the acquisition of Exact Sciences. Following the acquisition, the sales of Exact Sciences are presented as Abbott's Cancer Diagnostics business.
Sales 3Q26 ($ in Total Key Emerging Other millions) Markets U.S. — — — International 1,614 1,195 419 Total reported 1,614 1,195 419
% Change vs. 3Q25 U.S. n/a n/a n/a International 6.8 9.0 1.1 Total reported 6.8 9.0 1.1 Total reported excl. foreign exchange 8.4 10.9 1.6 impact Comparable sales growth 8.4 10.9 1.6 U.S. n/a n/a n/a International 8.4 10.9 1.6
Established Pharmaceuticals sales increased 6.8 percent on a reported basis and 8.4 percent on a comparable basis in the third quarter.
Key Emerging Markets include several emerging countries that represent the most attractive long-term growth opportunities for Abbott's branded generics product portfolio. Sales in these geographies increased 9.0 percent on a reported basis and 10.9 percent on a comparable basis, led by double-digit growth in India and several markets across the Latin America and Asia Pacific regions.
Sales 9M26 ($ in Total Key Emerging Other millions) Markets U.S. — — — International 4,539 3,448 1,091 Total reported 4,539 3,448 1,091
% Change vs. 9M25 U.S. n/a n/a n/a International 9.3 10.5 5.6 Total reported 9.3 10.5 5.6 Total reported excl. foreign exchange 8.7 10.4 3.6 impact Comparable sales growth 8.7 10.4 3.6 U.S. n/a n/a n/a International 8.7 10.4 3.6
Worldwide Medical Devices sales increased 6.9 percent on a reported basis and 7.8 percent on a comparable basis in the third quarter.
Sales growth in the quarter was led by double-digit growth in Electrophysiology and Rhythm Management.
In Diabetes Care, sales of continuous glucose monitors grew 7.3 percent on a reported basis and 7.7 percent on a comparable basis.
*Abbott's Amplatzer Amulet Left Atrial Appendage Occluder device and related accessories were transferred from Structural Heart to Electrophysiology on January 1, 2026. As a result, $55 million of sales in the third quarter of 2025 and $156 million of sales in the first nine months of 2025 were moved from Structural Heart to Electrophysiology.
Abbott projects full-year 2026 comparable sales growth to be approximately 6.0% 1 .
Abbott projects full-year 2026 adjusted diluted earnings per share of $5.50 to $5.55.
Abbott projects fourth-quarter 2026 adjusted diluted earnings per share of $1.62 to $1.67.
Abbott has not provided the related GAAP financial measures on a forward-looking basis for these forward-looking non-GAAP financial measures because the company is unable to predict with reasonable certainty and without unreasonable effort the timing and impact of certain items such as restructuring and cost reduction initiatives, charges for intangible asset impairments, acquisition-related expenses, and foreign exchange, which could significantly impact Abbott's results in accordance with GAAP.
On Sept. 17, 2026, the board of directors of Abbott declared the company's quarterly dividend of $0.63 per share. Abbott's cash dividend is payable Nov. 16, 2026, to shareholders of record at the close of business on Oct. 15, 2026.
Abbott has increased its dividend payout for 54 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years.
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 122,000 colleagues serve people in more than 160 countries.
Connect with us at www.abbott.com and on LinkedIn, Facebook, Instagram, X and YouTube.
Abbott will live-webcast its third-quarter earnings conference call through its Investor Relations website at www.abbottinvestor.com at 8 a.m. Central time today. An archived edition of the webcast will be available later in the day. Page 7 of 21 — Private Securities Litigation Reform Act of 1995 —
Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors" in our Annual Report on Form 10-K for the year ended Dec. 31, 2025, and are incorporated herein by reference. Abbott undertakes no obligation to release publicly any revisions to forward- looking statements as a result of subsequent events or developments, except as required by law.
Abbott Financial: Abbott Media: Michael Comilla, 224-668-1872 Karen Twigg May, 224-668-2681 Tamika McLoughlin, 224-399-5082 Kate Dyer, 224-668-9965 Randy Blakley, 224-668-0036
1. In 2025, total worldwide sales were $44.328 billion, which included U.S. sales of $17.126 billion and international sales of $27.202 billion, and Abbott’s Structural Heart business received $89 million of compensation payments as part of a multi-year agreement with a competitor. Also in 2025, total worldwide sales for Exact Sciences were $3.247 billion, which included U.S. sales of $3.145 billion and international sales of $102 million. Page 8 of 21 Abbott Laboratories and Subsidiaries
See tables on page 13 for an explanation of certain non-GAAP financial information.
See footnotes on the following page. Page 9 of 21 1) 2026 Taxes on Earnings includes the recognition of approximately $35 million of net tax expense primarily as a result of the resolution of various tax positions related to prior years. 2026 Taxes on Earnings also includes approximately $100 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.
2025 Taxes on Earnings includes approximately $160 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.
2) 2026 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $1.557 billion, or $0.89 per share, for intangible amortization, legal settlements, acquisitions, restructuring actions, and other net expenses.
2025 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $634 million, or $0.36 per share, for intangible amortization, charges related to restructuring and cost reduction initiatives, and other net expenses. Page 10 of 21 Abbott Laboratories and Subsidiaries
See tables on page 14 for an explanation of certain non-GAAP financial information.
See footnotes on the following page. Page 11 of 21 1) 2026 Taxes on Earnings includes the recognition of approximately $95 million of net tax expense primarily as a result of the resolution of various tax positions related to prior years. 2026 Taxes on Earnings also includes approximately $540 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.
2025 Taxes on Earnings includes the recognition of approximately $90 million of net tax benefit as a result of the resolution of various tax positions related to prior years. 2025 Taxes on Earnings also includes approximately $460 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit .
2) 2026 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $3.864 billion, or $2.21 per share, for intangible amortization, legal settlements, acquisitions, restructuring actions, and other net expenses.
2025 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $1.662 billion, or $0.95 per share, for intangible amortization, charges related to investment impairments, charges related to restructuring and cost reduction initiatives, expenses associated with acquisitions, and other net expenses. Page 12 of 21 Abbott Laboratories and Subsidiaries
Specified items reflect intangible amortization expense of $841 million, legal settlements of approximately $670 million and other net expenses of $178 million associated with acquisitions, restructuring actions, and other net expenses. See page 18 for additional details regarding specified items.
Specified items reflect intangible amortization expense of $420 million and other net expenses of $128 million associated with restructuring actions, costs associated with acquisitions, and other net expenses. See page 19 for additional details regarding specified items. Page 13 of 21 Abbott Laboratories and Subsidiaries
Specified items reflect intangible amortization expense of $1.921 billion, legal settlements of approximately $1.070 billion and other net expenses of $811 million associated with acquisitions, restructuring actions, and other net expenses. See page 20 for additional details regarding specified items.
Specified items reflect intangible amortization expense of $1.260 billion and other net expenses of $308 million associated with restructuring actions, acquisitions, investment impairment charges, and other net expenses. See page 21 for additional details regarding specified items. Page 14 of 21 A reconciliation of the third-quarter tax rates for 2026 and 2025 is shown below:
1) 2026 Taxes on Earnings includes the recognition of approximately $35 million of net tax expense primarily as a result of the resolution of various tax positions related to prior years. 2026 Taxes on Earnings also includes approximately $100 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.
2) 2025 Taxes on Earnings includes approximately $160 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.
A reconciliation of the year-to-date tax rates for 2026 and 2025 is shown below:
3) 2026 Taxes on Earnings includes the recognition of approximately $95 million of net tax expense primarily as a result of the resolution of various tax positions related to prior years. 2026 Taxes on Earnings also includes approximately $540 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.
4) 2025 Taxes on Earnings includes the recognition of approximately $90 million of net tax benefit as a result of the resolution of various tax positions related to prior years. 2025 Taxes on Earnings also includes approximately $460 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit. Page 15 of 21 Abbott Laboratories and Subsidiaries
Abbott's Amplatzer Amulet Left Atrial Appendage Occluder device and related accessories were transferred from Structural Heart to Electrophysiology on January 1, 2026. As a result, $55 million of sales in the third quarter of 2025 were moved from Structural Heart to Electrophysiology. The adjustment includes historical sales for Exact Sciences prior to the acquisition date. Exact Sciences was acquired by Abbott on March 23, 2026. Reflects the impact of compensation payments that Abbott's Structural Heart business received as part of a multi-year a) agreement with a competitor. The final payment under this agreement b) * was recognized in the first quarter of 2026. ──────────────────────────────────────────────────────────────────────────────
Abbott's Amplatzer Amulet Left Atrial Appendage Occluder device and related accessories were transferred from Structural Heart to Electrophysiology on January 1, 2026. As a result, $156 million of sales in the first nine months of 2025 were moved from Structural Heart to Electrophysiology. The adjustment includes historical sales for Exact Sciences prior to the acquisition date. Exact Sciences was acquired by Abbott on March 23, 2026. Reflects the impact of compensation payments that Abbott's Structural Heart business received as part of a multi-year a) agreement with a competitor. The final payment under this agreement b) * was recognized in the first quarter of 2026. ──────────────────────────────────────────────────────────────────────────────
The table above provides additional details regarding the specified items described on page 13.
a) Acquisition-related expenses include integration costs that represent incremental costs directly related to integrating acquired businesses, as well as other costs related to business acquisitions.
b) Restructuring and cost reduction initiative expenses include severance, outplacement, and other direct costs associated with specific restructuring plans.
c) Other primarily includes approximately $670 million related to agreements entered into to resolve the Gill case and the necrotizing enterocolitis (NEC) claims asserted on behalf of approximately 2,000 additional infants, as well as incremental costs to comply with the European Union's Medical Device Regulations (MDR) and In Vitro Diagnostics Medical Device Regulations (IVDR) requirements for previously approved products.
d) Reflects the net tax benefit associated with the specified items and recognition of a tax expense as a result of the resolution of various tax positions related to prior years. Taxes on Earnings includes approximately $100 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit. Page 18 of 21 Abbott Laboratories and Subsidiaries
The table above provides additional details regarding the specified items described on page 13.
a) Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating acquired businesses.
b) Restructuring and cost reduction initiative expenses include severance, outplacement, and other direct costs associated with specific restructuring plans and cost reduction initiatives.
c) Other includes incremental costs to comply with the European Union's Medical Device Regulations (MDR) and In Vitro Diagnostics Medical Device Regulations (IVDR) requirements for previously approved products.
d) Reflects the net tax benefit associated with the specified items. Taxes on Earnings includes approximately $160 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit. Page 19 of 21 Abbott Laboratories and Subsidiaries
The table above provides additional details regarding the specified items described on page 14.
a) Acquisition-related expenses include stock-based compensation recognized as expense from equity awards accelerated in connection with the Exact Sciences acquisition, integration costs that represent incremental costs directly related to integrating acquired businesses, as well as other costs related to business acquisitions, including inventory step-up amortization.
b) Restructuring and cost reduction initiative expenses include severance, outplacement and other direct costs associated with specific restructuring plans.
c) Other primarily includes approximately $670 million related to agreements entered into to resolve the Gill case and the NEC claims asserted on behalf of approximately 2,000 additional infants; approximately $400 million, including attorneys' fees and accrued interest, related to an agreement to resolve the United States Department of Justice (DOJ) investigations and the civil qui tam lawsuit brought by certain relators and joined by the DOJ and Attorneys General of several states; as well as incremental costs to comply with the European Union's Medical Device Regulations (MDR) and In Vitro Diagnostics Medical Device Regulations (IVDR) requirements for previously approved products.
d) Reflects the net tax benefit associated with the specified items and recognition of a tax expense as a result of the resolution of various tax positions related to prior years. Taxes on Earnings includes approximately $540 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit. Page 20 of 21 Abbott Laboratories and Subsidiaries
The table above provides additional details regarding the specified items described on page 14.
a) Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating acquired businesses, as well as other costs related to business acquisitions.
b) Restructuring and cost reduction initiative expenses include severance, outplacement, and other direct costs associated with specific restructuring plans and cost reduction initiatives.
c) Other includes incremental costs to comply with the MDR and IVDR regulations for previously approved products and charges for investment impairments.
d) Reflects the net tax benefit associated with the specified items and recognition of a tax benefit as a result of the resolution of various tax positions related to prior years. Taxes on Earnings includes approximately $460 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit. Page 21 of 21
Full text with the tables
Exhibit 99.1
News Release
Abbott Reports Third-Quarter 2026 Results and Reaffirms Full-Year EPS Guidance
– Third-quarter reported sales growth of 14.5 percent; comparable sales growth
of 7.0 percent
– Third-quarter GAAP diluted EPS of $0.53; adjusted diluted EPS of $1.42
– Expands portfolio with key new product approvals
ABBOTT PARK, Ill., Oct. 21, 2026 — Abbott today announced financial results for
the third quarter ended Sept. 30, 2026.
• Third-quarter sales increased 14.5 percent on a reported basis and 7.0 percent
on a comparable basis.
• Third-quarter GAAP diluted EPS of $0.53 and adjusted diluted EPS of $1.42,
which excludes specified items.
• Abbott projects full-year 2026 comparable sales growth to be approximately 6.0
percent 1 .
• Abbott reaffirms the midpoint of previously provided full-year 2026 adjusted
diluted EPS guidance range and tightens the range to $5.50 to $5.55.
• In August, Abbott announced U.S. Food and Drug Administration (FDA) approval
for Libre® Duo, the world's first dual glucose-ketone biowearable sensor. By
providing real-time visibility into glucose and ketone levels, this new
technology helps optimize the management of diabetes by detecting rising ketone
levels, which can lead to diabetic ketoacidosis, a serious health condition for
people with diabetes.
• In August, Abbott announced that the company received CE Mark for its Amulet
360™ Left Atrial Appendage (LAA) Occluder, a next-generation device designed to
reduce the risk of stroke in patients with atrial fibrillation (AFib).
• In August, Abbott announced the launch of Similac® 360 Total Care® Made With
Whole Milk — the first and only commercially sterile, ready-to-feed liquid
infant formula made with whole milk in the United States.
• In September, Abbott announced FDA approval for its TactiFlex™ Duo Ablation
Catheter, Sensor Enabled™, designed to deliver both pulsed field ablation (PFA)
and radiofrequency (RF) energy to treat patients battling atrial fibrillation.
• In September, Abbott launched SimpleScreen™ CRC, an FDA-approved, blood-based
colorectal cancer screening test for adults age 45 and older who are at average
risk for the disease.
"Abbott delivered strong third-quarter results, reflecting balanced growth
across our portfolio," said Robert B. Ford, chairman and chief executive
officer, Abbott. "With strong performance across multiple businesses and a
robust pipeline of innovation, we are well-positioned to deliver sustainable
growth in the years ahead."
Page 1 of 21
THIRD-QUARTER BUSINESS OVERVIEW
Comparable sales growth:
Management believes that measuring sales growth on a comparable basis is an
appropriate way for investors to best understand the underlying performance of
the business. Comparable sales growth includes the prior and current year sales
of Exact Sciences, a cancer diagnostics company that Abbott acquired on March
23, 2026. Comparable sales growth excludes the impact of foreign exchange and
revenue in both the prior and current year related to compensation payments that
Abbott's Structural Heart business received as part of a multi-year agreement
with a competitor. The final payment under this agreement was recognized in the
first quarter of 2026.
Note: In order to compute results excluding the impact of exchange rates,
current year U.S. dollar sales are multiplied or divided, as appropriate, by the
current year average foreign exchange rates and then those amounts are
multiplied or divided, as appropriate, by the prior year average foreign
exchange rates.
Third Quarter 2026 Results (3Q26)
Sa…
3Q… Tot… Esta… Medi…
($ Com… Nut… Diag… Phar… Devi…
in
mi…
U.… 5,5… 958 1,8… — 2,6…
In… 7,5… 1,3… 1,4… 1,6… 3,1…
To… 13,… 2,2… 3,3… 1,6… 5,8…
re…
% Change vs. 3Q25
U.S. 28.0 7.9 109.2 n/a 6.6
International 6.2 3.1 6.2 6.8 7.2
Total reported 14.5 5.1 46.7 6.8 6.9
Total reported excl. foreign
exchange 14.8 4.9 46.6 8.4 7.4
impact
Comparable sales growth 7.0 4.9 6.4 8.4 7.8
U.S. 7.9 7.9 8.4 n/a 7.6
International 6.4 2.8 4.0 8.4 8.0
First Nine Months 2026 Results (9M26)
Sa…
9M… Tot… Esta… Medi…
($ Com… Nut… Diag… Phar… Devi…
in
mi…
U.… 14,… 2,6… 4,4… — 7,8…
In… 21,… 3,7… 4,1… 4,5… 9,3…
To… 36,… 6,4… 8,5… 4,5… 17,…
re…
% Change vs. 9M25
U.S. 17.7 -4.5 72.0 n/a 7.1
International 8.2 1.1 6.3 9.3 11.7
Total reported 11.9 -1.3 32.4 9.3 9.6
Total reported excl. foreign
exchange 10.5 -2.1 30.8 8.7 7.8
impact
Comparable sales growth 5.2 -2.1 3.8 8.7 8.2
U.S. 4.7 -4.5 4.9 n/a 8.1
International 5.7 -0.3 2.4 8.7 8.3
Refer to pages 16 and 17 for a reconciliation of comparable sales growth.
Page 2 of 21
Nutrition
Third Quarter 2026 Results (3Q26)
Sales 3Q26 ($ in Total Pediatric Adult
millions)
U.S. 958 577 381
International 1,304 486 818
Total reported 2,262 1,063 1,199
% Change vs. 3Q25
U.S. 7.9 11.0 3.5
International 3.1 6.4 1.3
Total reported 5.1 8.8 2.0
Total reported excl. foreign exchange 4.9 8.7 1.8
impact
Comparable sales growth 4.9 8.7 1.8
U.S. 7.9 11.0 3.5
International 2.8 6.0 1.0
Worldwide Nutrition sales increased 5.1 percent on a reported basis and 4.9
percent on a comparable basis in the third quarter.
Worldwide Nutrition results were driven by broad-based growth across the
portfolio, including sales growth of nearly 9.0 percent in Worldwide Pediatric.
On a sequential basis, Worldwide Nutrition sales increased $118 million compared
to the second quarter of 2026.
First Nine Months 2026 Results (9M26)
Sales 9M26 ($ in Total Pediatric Adult
millions)
U.S. 2,673 1,613 1,060
International 3,750 1,428 2,322
Total reported 6,423 3,041 3,382
% Change vs. 9M25
U.S. -4.5 -4.8 -4.0
International 1.1 3.7 -0.5
Total reported -1.3 -1.0 -1.6
Total reported excl. foreign exchange -2.1 -1.6 -2.6
impact
Comparable sales growth -2.1 -1.6 -2.6
U.S. -4.5 -4.8 -4.0
International -0.3 2.4 -2.0
Page 3 of 21
Diagnostics*
Third Quarter 2026 Results (3Q26)
Sales
3Q26 ($ Total Core Cancer Rapid/M…
in Laborat… Diagnos… Diagnos…
millio…
U.S. 1,853 389 938 526
Intern… 1,452 1,049 30 373
Total 3,305 1,438 968 899
report…
% Change vs. 3Q25
U.S. 109.2 6.3 n/a 1.1
International 6.2 5.1 n/a 1.0
Total reported 46.7 5.4 n/a 1.1
Total reported excl. foreign exchange 46.6 5.4 n/a 0.9
impact
Comparable sales growth 6.4 5.4 13.8 0.9
U.S. 8.4 6.3 13.9 1.1
International 4.0 5.1 12.1 0.7
Worldwide Diagnostics sales increased 46.7 percent on a reported basis and 6.4
percent on a comparable basis in the third quarter.
Worldwide Core Laboratory Diagnostics results were driven by balanced growth
across major geographic regions including the U.S., Europe, Japan, and Latin
America.
Cancer Diagnostics results were driven by growth of Cologuard® and also reflect
contributions to growth from the precision oncology and international
businesses.
First Nine Months 2026 Results (9M26)
Sales
9M26 Total Core Cancer Rapid/…
($ in Labora… Diagno… Diagno…
milli…
U.S. 4,418 1,113 1,921 1,384
Inter… 4,159 3,015 62 1,082
Total 8,577 4,128 1,983 2,466
repor…
% Change vs. 9M25
U.S. 72.0 6.1 n/a -8.9
International 6.3 5.8 n/a 1.9
Total reported 32.4 5.9 n/a -4.5
Total reported excl. foreign exchange 30.8 4.0 n/a -5.4
impact
Comparable sales growth 3.8 4.0 13.5 -5.4
U.S. 4.9 6.1 13.5 -8.9
International 2.4 3.2 15.0 -0.4
*Beginning in 2026, Abbott aggregated its previously reported Rapid Diagnostics,
Molecular Diagnostics, and Point of Care businesses into the Rapid and Molecular
Diagnostics business. On March 23, 2026, Abbott completed the acquisition of
Exact Sciences. Following the acquisition, the sales of Exact Sciences are
presented as Abbott's Cancer Diagnostics business.
Refer to pages 16 and 17 for a reconciliation of comparable sales growth.
Page 4 of 21
Established Pharmaceuticals
Third Quarter 2026 Results (3Q26)
Sales 3Q26 ($ in Total Key Emerging Other
millions) Markets
U.S. — — —
International 1,614 1,195 419
Total reported 1,614 1,195 419
% Change vs. 3Q25
U.S. n/a n/a n/a
International 6.8 9.0 1.1
Total reported 6.8 9.0 1.1
Total reported excl. foreign exchange 8.4 10.9 1.6
impact
Comparable sales growth 8.4 10.9 1.6
U.S. n/a n/a n/a
International 8.4 10.9 1.6
Established Pharmaceuticals sales increased 6.8 percent on a reported basis and
8.4 percent on a comparable basis in the third quarter.
Key Emerging Markets include several emerging countries that represent the most
attractive long-term growth opportunities for Abbott's branded generics product
portfolio. Sales in these geographies increased 9.0 percent on a reported basis
and 10.9 percent on a comparable basis, led by double-digit growth in India and
several markets across the Latin America and Asia Pacific regions.
First Nine Months 2026 Results (9M26)
Sales 9M26 ($ in Total Key Emerging Other
millions) Markets
U.S. — — —
International 4,539 3,448 1,091
Total reported 4,539 3,448 1,091
% Change vs. 9M25
U.S. n/a n/a n/a
International 9.3 10.5 5.6
Total reported 9.3 10.5 5.6
Total reported excl. foreign exchange 8.7 10.4 3.6
impact
Comparable sales growth 8.7 10.4 3.6
U.S. n/a n/a n/a
International 8.7 10.4 3.6
Page 5 of 21
Medical Devices
Third Quarter 2026 Results (3Q26)
…
… R… … … …
… T… M… E… … … … … …
…
…
… 2… 3… 4… 3… 2… 2… 1… 8…
… 3… 3… 4… 84 4… 3… 66 1…
… 5… 7… 8… 3… 7… 5… 2… 2…
…
% Change vs.
3Q25
U.S. 6.6 9.0 18.1 8.4 3.4 -11.1 -5.6 9.4
International 7.2 10.4 12.2 -2.7 6.7 12.2 13.6 4.2
Total reported 6.9 9.7 15.0 5.8 5.4 1.9 -1.2 6.2
Total reported
excl. foreign 7.4 10.0 15.5 6.0 5.7 2.6 -1.1 6.7
exchange
impact
Comparable 7.8 10.0 15.5 6.0 5.7 6.9 -1.1 6.7
sales growth
U.S. 7.6 9.0 18.1 8.4 3.4 -2.3 -5.6 9.4
International 8.0 11.0 13.1 -1.6 7.1 13.5 13.9 4.9
Worldwide Medical Devices sales increased 6.9 percent on a reported basis and
7.8 percent on a comparable basis in the third quarter.
Sales growth in the quarter was led by double-digit growth in Electrophysiology
and Rhythm Management.
In Diabetes Care, sales of continuous glucose monitors grew 7.3 percent on a
reported basis and 7.7 percent on a comparable basis.
First Nine Months 2026 Results (9M26)
…
… R… … … …
… T… M… E… … … … … …
…
…
… 7… 1… 1… 9… 8… 6… 5… 2…
… 9… 1… 1… 2… 1… 1… 2… 3…
… 1… 2… 2… 1… 2… 1… 7… 6…
…
% Change vs.
9M25
U.S. 7.1 10.4 16.0 10.2 5.2 -10.2 -2.4 9.3
Internation… 11.7 13.9 14.5 7.9 8.0 16.1 18.1 10.5
Total 9.6 12.1 15.2 9.7 7.0 4.4 2.4 10.0
reported
Total
reported
excl. 7.8 10.6 13.8 8.9 5.2 2.6 1.3 7.7
foreign
exchange
impact
Comparable 8.2 10.6 13.8 8.9 5.2 6.5 1.3 7.7
sales growth
U.S. 8.1 10.4 16.0 10.2 5.2 -2.3 -2.4 9.3
Internation… 8.3 10.8 11.9 4.6 5.2 12.8 13.5 6.6
*Abbott's Amplatzer Amulet Left Atrial Appendage Occluder device and related
accessories were transferred from Structural Heart to Electrophysiology on
January 1, 2026. As a result, $55 million of sales in the third quarter of 2025
and $156 million of sales in the first nine months of 2025 were moved from
Structural Heart to Electrophysiology.
Refer to pages 16 and 17 for a reconciliation of comparable sales growth.
Page 6 of 21
Abbott's Financial Guidance
Abbott projects full-year 2026 comparable sales growth to be approximately 6.0%
1 .
Abbott projects full-year 2026 adjusted diluted earnings per share of $5.50 to
$5.55.
Abbott projects fourth-quarter 2026 adjusted diluted earnings per share of $1.62
to $1.67.
Abbott has not provided the related GAAP financial measures on a forward-looking
basis for these forward-looking non-GAAP financial measures because the company
is unable to predict with reasonable certainty and without unreasonable effort
the timing and impact of certain items such as restructuring and cost reduction
initiatives, charges for intangible asset impairments, acquisition-related
expenses, and foreign exchange, which could significantly impact Abbott's
results in accordance with GAAP.
Abbott Declares 411
th
Consecutive Quarterly Dividend
On Sept. 17, 2026, the board of directors of Abbott declared the company's
quarterly dividend of $0.63 per share. Abbott's cash dividend is payable Nov.
16, 2026, to shareholders of record at the close of business on Oct. 15, 2026.
Abbott has increased its dividend payout for 54 consecutive years and is a
member of the S&P 500 Dividend Aristocrats Index, which tracks companies that
have annually increased their dividend for at least 25 consecutive years.
About Abbott:
Abbott is a global healthcare leader that helps people live more fully at all
stages of life. Our portfolio of life-changing technologies spans the spectrum
of healthcare, with leading businesses and products in diagnostics, medical
devices, nutritionals and branded generic medicines. Our 122,000 colleagues
serve people in more than 160 countries.
Connect with us at www.abbott.com and on LinkedIn, Facebook, Instagram, X and
YouTube.
Abbott will live-webcast its third-quarter earnings conference call through its
Investor Relations website at www.abbottinvestor.com at 8 a.m. Central time
today. An archived edition of the webcast will be available later in the day.
Page 7 of 21
— Private Securities Litigation Reform Act of 1995 —
A Caution Concerning Forward-Looking Statements
Some statements in this news release may be forward-looking statements for
purposes of the Private Securities Litigation Reform Act of 1995. Abbott
cautions that these forward-looking statements are subject to risks and
uncertainties that may cause actual results to differ materially from those
indicated in the forward-looking statements. Economic, competitive,
governmental, technological and other factors that may affect Abbott's
operations are discussed in Item 1A, "Risk Factors" in our Annual Report on Form
10-K for the year ended Dec. 31, 2025, and are incorporated herein by reference.
Abbott undertakes no obligation to release publicly any revisions to forward-
looking statements as a result of subsequent events or developments, except as
required by law.
Abbott Financial: Abbott Media:
Michael Comilla, 224-668-1872 Karen Twigg May, 224-668-2681
Tamika McLoughlin, 224-399-5082 Kate Dyer, 224-668-9965
Randy Blakley, 224-668-0036
1. In 2025, total worldwide sales were $44.328 billion, which included U.S.
sales of $17.126 billion and international sales of $27.202 billion, and
Abbott’s Structural Heart business received $89 million of compensation payments
as part of a multi-year agreement with a competitor. Also in 2025, total
worldwide sales for Exact Sciences were $3.247 billion, which included U.S.
sales of $3.145 billion and international sales of $102 million.
Page 8 of 21
Abbott Laboratories and Subsidiaries
Condensed Consolidated Statement of Earnings
Third Quarter Ended September 30, 2026 and 2025
(in millions, except per share data)
(unaudited)
3Q26 3Q25 %
Chan…
Net $13,… $11,3… 14.5
Sales
Cost
of
prod…
sold, 5,628 5,075 10.9
excl…
amor…
expe…
Amor…
of 841 420 n/m
inta…
asse…
Rese…
and 920 766 20.1
deve…
Sell…
gene… 4,266 3,051 39.8
and
admi…
Total
Oper…
Cost 11,655 9,312 25.2
and
Expe…
Oper… 1,358 2,057 -34.0
Earn…
Inte…
expe… 297 44 n/m
net
Net
fore…
exch… -6 -17 n/m
(gai…
loss
Other
(inc… -164 -150 9.4
expe…
net
Earn…
befo… 1,231 2,180 -43.5
taxes
Taxes
on 311 536 -42.0 1)
Earn…
Net $920 $1,644 -44.1
Earn…
Net
Earn…
excl…
Spec… $2,4… $2,278 8.7 2)
Item…
as
desc…
below
Dilu…
Earn…
per $0.53 $0.94 -43.6
Comm…
Share
Dilu…
Earn…
per
Comm…
Shar…
excl… $1.42 $1.30 9.2 2)
Spec…
Item…
as
desc…
below
Aver…
Numb…
of
Comm…
Shar…
Outs… 1,738 1,749
Plus
Dilu…
Comm…
Stock
Opti…
NOTES:
See tables on page 13 for an explanation of certain non-GAAP financial
information.
n/m = Percent change is not meaningful.
See footnotes on the following page.
Page 9 of 21
1) 2026 Taxes on Earnings includes the recognition of approximately $35 million
of net tax expense primarily as a result of the resolution of various tax
positions related to prior years. 2026 Taxes on Earnings also includes
approximately $100 million in adjustments related to prior recognition of a
significant non-cash deferred tax benefit.
2025 Taxes on Earnings includes approximately $160 million in adjustments
related to prior recognition of a significant non-cash deferred tax benefit.
2) 2026 Net Earnings and Diluted Earnings per Common Share, excluding Specified
Items, excludes net after-tax charges of $1.557 billion, or $0.89 per share, for
intangible amortization, legal settlements, acquisitions, restructuring actions,
and other net expenses.
2025 Net Earnings and Diluted Earnings per Common Share, excluding Specified
Items, excludes net after-tax charges of $634 million, or $0.36 per share, for
intangible amortization, charges related to restructuring and cost reduction
initiatives, and other net expenses.
Page 10 of 21
Abbott Laboratories and Subsidiaries
Condensed Consolidated Statement of Earnings
Nine Months Ended September 30, 2026 and 2025
(in millions, except per share data)
(unaudited)
9M26 9M25 %
Chan…
Net $36,7… $32,8… 11.9
Sales
Cost
of
prod…
sold, 15,8… 14,3… 10.0
excl…
amor…
expe…
Amor…
of 1,921 1,260 52.4
inta…
asse…
Rese…
and 2,579 2,207 16.9
deve…
Sell…
gene… 12,0… 9,203 30.7
and
admi…
Total
Oper…
Cost 32,3… 27,0… 19.6
and
Expe…
Oper… 4,396 5,802 -24.2
Earn…
Inte…
expe… 664 143 n/m
net
Net
fore…
exch… -15 -35 n/m
(gai…
loss
Other
(inc… -457 -414 10.2
expe…
net
Earn…
befo… 4,204 6,108 -31.2
taxes
Taxes
on 1,279 1,360 -6.0 1)
earn…
Net $2,925 $4,748 -38.4
Earn…
Net
Earn…
excl…
Spec… $6,789 $6,410 5.9 2)
Item…
as
desc…
below
Dilu…
Earn…
per $1.67 $2.70 -38.1
Comm…
Share
excl…
Spec…
Item… $3.88 $3.65 6.3 2)
as
desc…
below
Plus
Dilu…
Comm… 1,743 1,749
Stock
Opti…
NOTES:
See tables on page 14 for an explanation of certain non-GAAP financial
information.
n/m = Percent change is not meaningful.
See footnotes on the following page.
Page 11 of 21
1) 2026 Taxes on Earnings includes the recognition of approximately $95 million
of net tax expense primarily as a result of the resolution of various tax
positions related to prior years. 2026 Taxes on Earnings also includes
approximately $540 million in adjustments related to prior recognition of a
significant non-cash deferred tax benefit.
2025 Taxes on Earnings includes the recognition of approximately $90 million of
net tax benefit as a result of the resolution of various tax positions related
to prior years. 2025 Taxes on Earnings also includes approximately $460 million
in adjustments related to prior recognition of a significant non-cash deferred
tax benefit .
2) 2026 Net Earnings and Diluted Earnings per Common Share, excluding Specified
Items, excludes net after-tax charges of $3.864 billion, or $2.21 per share, for
intangible amortization, legal settlements, acquisitions, restructuring actions,
and other net expenses.
2025 Net Earnings and Diluted Earnings per Common Share, excluding Specified
Items, excludes net after-tax charges of $1.662 billion, or $0.95 per share, for
intangible amortization, charges related to investment impairments, charges
related to restructuring and cost reduction initiatives, expenses associated
with acquisitions, and other net expenses.
Page 12 of 21
Abbott Laboratories and Subsidiaries
Non-GAAP Reconciliation of Financial Information
Third Quarter Ended September 30, 2026 and 2025
(in millions, except per share data)
(unaudited)
3Q26
As Reported Specified
(GAAP) Items As Adjusted
──────────────────────────────────────────────────────────────────────────────
Intangible $ 841 $ -841 $ —
Amortizat…
Gross 6,544 904 7,448
Margin
R&D 920 -28 892
SG&A 4,266 -761 3,505
Other
(income) -164 4 -160
expense,
net
Earnings
before 1,231 1,689 2,920
taxes
Taxes on 311 132 443
Earnings
Net 920 1,557 2,477
Earnings
Diluted
Earnings $ 0.53 $ 0.89 $ 1.42
per Share
Specified items reflect intangible amortization expense of $841 million, legal
settlements of approximately $670 million and other net expenses of $178 million
associated with acquisitions, restructuring actions, and other net expenses. See
page 18 for additional details regarding specified items.
3Q25
As Reported Specified
(GAAP) Items As Adjusted
──────────────────────────────────────────────────────────────────────────────
Intangible $ 420 $ -420 $ —
Amortizat…
Gross 5,874 470 6,344
Margin
R&D 766 -36 730
SG&A 3,051 -47 3,004
Other
(income) -150 5 -145
expense,
net
Earnings
before 2,180 548 2,728
taxes
Taxes on 536 -86 450
Earnings
Net 1,644 634 2,278
Earnings
Diluted
Earnings $ 0.94 $ 0.36 $ 1.30
per Share
Specified items reflect intangible amortization expense of $420 million and
other net expenses of $128 million associated with restructuring actions, costs
associated with acquisitions, and other net expenses. See page 19 for additional
details regarding specified items.
Page 13 of 21
Abbott Laboratories and Subsidiaries
Non-GAAP Reconciliation of Financial Information
Nine Months Ended September 30, 2026 and 2025
(in millions, except per share data)
(unaudited)
9M26
As
Reported Specified As
(GAAP) Items Adjusted
──────────────────────────────────────────────────────────────────────────────
Intangible $ 1,921 $ -1,921 $ —
Amortizat…
Gross 19,006 2,033 21,039
Margin
R&D 2,579 -77 2,502
SG&A 12,031 -1,662 10,369
Other
(income) -457 -30 -487
expense,
net
Earnings
before 4,204 3,802 8,006
taxes
Taxes on 1,279 -62 1,217
Earnings
Net 2,925 3,864 6,789
Earnings
Diluted
Earnings $ 1.67 $ 2.21 $ 3.88
per Share
Specified items reflect intangible amortization expense of $1.921 billion, legal
settlements of approximately $1.070 billion and other net expenses of $811
million associated with acquisitions, restructuring actions, and other net
expenses. See page 20 for additional details regarding specified items.
9M25
As
Reported Specified As
(GAAP) Items Adjusted
──────────────────────────────────────────────────────────────────────────────
Intangible $ 1,260 $ -1,260 $ —
Amortizat…
Gross 17,212 1,396 18,608
Margin
R&D 2,207 -83 2,124
SG&A 9,203 -58 9,145
Other
(income) -414 -31 -445
expense,
net
Earnings
before 6,108 1,568 7,676
taxes
Taxes on 1,360 -94 1,266
Earnings
Net 4,748 1,662 6,410
Earnings
Diluted
Earnings $ 2.70 $ 0.95 $ 3.65
per Share
Specified items reflect intangible amortization expense of $1.260 billion and
other net expenses of $308 million associated with restructuring actions,
acquisitions, investment impairment charges, and other net expenses. See page 21
for additional details regarding specified items.
Page 14 of 21
A reconciliation of the third-quarter tax rates for 2026 and 2025 is shown
below:
3Q26
Pre-Tax Taxes on Tax
($ in millions) Income Earnings Rate
──────────────────────────────────────────────────────────────────────────────
As reported (GAAP) $ 1,231 $ 311 25.3 % 1)
Specified items 1,689 132
Excluding $ 2,920 $ 443 15.2 %
specified items
3Q25
Pre-Tax Taxes on Tax
($ in millions) Income Earnings Rate
──────────────────────────────────────────────────────────────────────────────
As reported (GAAP) $ 2,180 $ 536 24.6 % 2)
Specified items 548 -86
Excluding $ 2,728 $ 450 16.5 %
specified items
1) 2026 Taxes on Earnings includes the recognition of approximately $35 million
of net tax expense primarily as a result of the resolution of various tax
positions related to prior years. 2026 Taxes on Earnings also includes
approximately $100 million in adjustments related to prior recognition of a
significant non-cash deferred tax benefit.
2) 2025 Taxes on Earnings includes approximately $160 million in adjustments
related to prior recognition of a significant non-cash deferred tax benefit.
A reconciliation of the year-to-date tax rates for 2026 and 2025 is shown below:
9M26
Pre-Tax Taxes on Tax
($ in millions) Income Earnings Rate
──────────────────────────────────────────────────────────────────────────────
As reported $ 4,204 $ 1,279 30.4 % 3)
(GAAP)
Specified items 3,802 -62
Excluding $ 8,006 $ 1,217 15.2 %
specified items
9M25
Pre-Tax Taxes on Tax
($ in millions) Income Earnings Rate
──────────────────────────────────────────────────────────────────────────────
As reported $ 6,108 $ 1,360 22.3 % 4)
(GAAP)
Specified items 1,568 -94
Excluding $ 7,676 $ 1,266 16.5 %
specified items
3) 2026 Taxes on Earnings includes the recognition of approximately $95 million
of net tax expense primarily as a result of the resolution of various tax
positions related to prior years. 2026 Taxes on Earnings also includes
approximately $540 million in adjustments related to prior recognition of a
significant non-cash deferred tax benefit.
4) 2025 Taxes on Earnings includes the recognition of approximately $90 million
of net tax benefit as a result of the resolution of various tax positions
related to prior years. 2025 Taxes on Earnings also includes approximately $460
million in adjustments related to prior recognition of a significant non-cash
deferred tax benefit.
Page 15 of 21
Abbott Laboratories and Subsidiaries
Non-GAAP Revenue Reconciliation
Third Quarter Ended September 30, 2026 and 2025
($ in millions)
(unaudited)
%
… … …
…
…
N…
… …
… … … … … … …
… … … … … … … … C…
… …
…
… … … … … … … … …
… — … … … … … … …
… … … … … — … … …
… … … … … — … … …
… — … … … — … … …
… … … … … — … … …
… — … — … — … … …
… — … — … — … … …
… — … — … — … … …
… … … … — … … … …
… — … … — … … … …
… … … … — — … … …
… 4 … … — … … … …
… — … … — … … … …
… 4 … … — — … … …
Abbott's Amplatzer Amulet Left Atrial Appendage Occluder device and
related accessories were transferred from Structural Heart to
Electrophysiology on January 1, 2026. As a result, $55 million of
sales in the third quarter of 2025 were moved from Structural Heart
to Electrophysiology.
The adjustment includes historical sales for Exact Sciences prior
to the acquisition date. Exact Sciences was acquired by Abbott on
March 23, 2026.
Reflects the impact of compensation payments that Abbott's
Structural Heart business received as part of a multi-year
a) agreement with a competitor. The final payment under this agreement
b) * was recognized in the first quarter of 2026.
──────────────────────────────────────────────────────────────────────────────
Page 16 of 21
Abbott Laboratories and Subsidiaries
Non-GAAP Revenue Reconciliation
Nine Months Ended September 30, 2026 and 2025
($ in millions)
(unaudited)
%
… …
…
…
… …
… … … … … …
… … … … … … …
… …
…
…
…
…
…
…
…
… …
… …
… …
…
…
…
…
…
…
Abbott's Amplatzer Amulet Left Atrial Appendage Occluder device and
related accessories were transferred from Structural Heart to
Electrophysiology on January 1, 2026. As a result, $156 million of
sales in the first nine months of 2025 were moved from Structural
Heart to Electrophysiology.
The adjustment includes historical sales for Exact Sciences prior
to the acquisition date. Exact Sciences was acquired by Abbott on
March 23, 2026.
Reflects the impact of compensation payments that Abbott's
Structural Heart business received as part of a multi-year
a) agreement with a competitor. The final payment under this agreement
b) * was recognized in the first quarter of 2026.
──────────────────────────────────────────────────────────────────────────────
Page 17 of 21
Abbott Laboratories and Subsidiaries
Details of Specified Items
Third Quarter Ended September 30, 2026
(in millions, except per share data)
(unaudited)
Rest…
Acqu… and
or Cost
Dive… Redu…
rela… Init… Inta… Other Total
(a) (b) Amor… (c) Spec…
──────────────────────────────────────────────────────────────────────────────
Gro… $ 10 $ 29 $ 841 $ 24 $ 904
Mar…
R&D -7 -5 — -16 -28
SG&A -47 -20 — -694 -761
Oth…
(in… -8 -1 — 13 4
exp…
net
Ear…
bef… $ 72 $ 55 $ 841 $ 721 1,6…
tax…
Tax…
on 132
Ear…
(d)
Net $ 1,5…
Ear…
Dil…
Ear… $ 0.89
per
Sha…
The table above provides additional details regarding the specified items
described on page 13.
a) Acquisition-related expenses include integration costs that represent
incremental costs directly related to integrating acquired businesses, as well
as other costs related to business acquisitions.
b) Restructuring and cost reduction initiative expenses include severance,
outplacement, and other direct costs associated with specific restructuring
plans.
c) Other primarily includes approximately $670 million related to agreements
entered into to resolve the Gill case and the necrotizing enterocolitis (NEC)
claims asserted on behalf of approximately 2,000 additional infants, as well as
incremental costs to comply with the European Union's Medical Device Regulations
(MDR) and In Vitro Diagnostics Medical Device Regulations (IVDR) requirements
for previously approved products.
d) Reflects the net tax benefit associated with the specified items and
recognition of a tax expense as a result of the resolution of various tax
positions related to prior years. Taxes on Earnings includes approximately $100
million in adjustments related to prior recognition of a significant non-cash
deferred tax benefit.
Page 18 of 21
Abbott Laboratories and Subsidiaries
Details of Specified Items
Third Quarter Ended September 30, 2025
(in millions, except per share data)
(unaudited)
Rest…
Acqu… and
or Cost
Dive… Redu…
rela… Init… Intan… Other Total
(a) (b) Amort… (c) Speci…
──────────────────────────────────────────────────────────────────────────────
Gro… $ — $ 44 $ 420 $ 6 $ 470
Mar…
R&D — -19 — -17 -36
SG&A -9 -43 — 5 -47
Oth…
(in… 7 — — -2 5
exp…
net
Ear…
bef… $ 2 $ 106 $ 420 $ 20 548
tax…
Tax…
on -86
Ear…
(d)
Net $ 634
Ear…
Dil…
Ear… $ 0.36
per
Sha…
The table above provides additional details regarding the specified items
described on page 13.
a) Acquisition-related expenses include integration costs, which represent
incremental costs directly related to integrating acquired businesses.
b) Restructuring and cost reduction initiative expenses include severance,
outplacement, and other direct costs associated with specific restructuring
plans and cost reduction initiatives.
c) Other includes incremental costs to comply with the European Union's Medical
Device Regulations (MDR) and In Vitro Diagnostics Medical Device Regulations
(IVDR) requirements for previously approved products.
d) Reflects the net tax benefit associated with the specified items. Taxes on
Earnings includes approximately $160 million in adjustments related to prior
recognition of a significant non-cash deferred tax benefit.
Page 19 of 21
Abbott Laboratories and Subsidiaries
Details of Specified Items
Nine Months Ended September 30, 2026
(in millions, except per share data)
(unaudited)
Res…
Acqu… and
or Cost
Dive… Red…
rela… Ini… Inta… Other Total
(a) (b) Amor… (c) Spec…
──────────────────────────────────────────────────────────────────────────────
Gr… $ 44 $ 40 $ 1,9… $ 28 $ 2,0…
Ma…
R&D -18 -15 — -44 -77
SG… -533 -54 — -1,… -1,…
Ot…
(i… -9 -4 — -17 -30
ex…
net
Ea…
be… $ 604 $ 113 $ 1,9… $ 1,1… 3,8…
ta…
Ta…
on -62
Ea…
(d)
Net $ 3,8…
Ea…
Di…
Ea… $ 2.21
per
Sh…
The table above provides additional details regarding the specified items
described on page 14.
a) Acquisition-related expenses include stock-based compensation recognized as
expense from equity awards accelerated in connection with the Exact Sciences
acquisition, integration costs that represent incremental costs directly related
to integrating acquired businesses, as well as other costs related to business
acquisitions, including inventory step-up amortization.
b) Restructuring and cost reduction initiative expenses include severance,
outplacement and other direct costs associated with specific restructuring
plans.
c) Other primarily includes approximately $670 million related to agreements
entered into to resolve the Gill case and the NEC claims asserted on behalf of
approximately 2,000 additional infants; approximately $400 million, including
attorneys' fees and accrued interest, related to an agreement to resolve the
United States Department of Justice (DOJ) investigations and the civil qui tam
lawsuit brought by certain relators and joined by the DOJ and Attorneys General
of several states; as well as incremental costs to comply with the European
Union's Medical Device Regulations (MDR) and In Vitro Diagnostics Medical Device
Regulations (IVDR) requirements for previously approved products.
d) Reflects the net tax benefit associated with the specified items and
recognition of a tax expense as a result of the resolution of various tax
positions related to prior years. Taxes on Earnings includes approximately $540
million in adjustments related to prior recognition of a significant non-cash
deferred tax benefit.
Page 20 of 21
Abbott Laboratories and Subsidiaries
Details of Specified Items
Nine Months Ended September 30, 2025
(in millions, except per share data)
(unaudited)
Rest…
Acqu… and
or Cost
Dive… Redu…
rela… Init… Inta… Oth… Total
(a) (b) Amor… (c) Spec…
──────────────────────────────────────────────────────────────────────────────
Gro… $ 1 $ 125 $ 1,260 $ 10 $ 1,3…
Mar…
R&D -1 -42 — -40 -83
SG&A -15 -49 — 6 -58
Oth…
(in… -18 — — -13 -31
exp…
net
Ear…
bef… $ 35 $ 216 $ 1,260 $ 57 1,5…
tax…
Tax…
on -94
Ear…
(d)
Net $ 1,6…
Ear…
Dil…
Ear… $ 0.95
per
Sha…
The table above provides additional details regarding the specified items
described on page 14.
a) Acquisition-related expenses include integration costs, which represent
incremental costs directly related to integrating acquired businesses, as well
as other costs related to business acquisitions.
b) Restructuring and cost reduction initiative expenses include severance,
outplacement, and other direct costs associated with specific restructuring
plans and cost reduction initiatives.
c) Other includes incremental costs to comply with the MDR and IVDR regulations
for previously approved products and charges for investment impairments.
d) Reflects the net tax benefit associated with the specified items and
recognition of a tax benefit as a result of the resolution of various tax
positions related to prior years. Taxes on Earnings includes approximately $460
million in adjustments related to prior recognition of a significant non-cash
deferred tax benefit.
Page 21 of 21